Table 4 Change in quality of life in the IER + RE and RE groups between baseline and cycle 3 (Week 9 of the trial).

From: Randomised phase-2 screening trial of intermittent energy restriction plus resistance exercise versus resistance exercise alone during chemotherapy for advanced breast cancer

Quality of life measure

IER + RE (n = 35)

RE (n = 33)

All n = 68

p value IER + RE vs RE

FACT

n = 27

n = 21

n = 48

 

 FACT-B

4.0 (–0.8, 11.0)

1.0 (–4.0, 4.0)

1.9 (–3.0, 9.2)

0.031

 FACT-ES

6.0 (–1.9, 19.5)

1.0 (–3.0, 8.7)

3.5 (–3.0, 14.0)

0.157

 FACT-G

4 (–4.7, 13.0)

–0.2 (–4.4, 4.0)

1.5 (–4.6, 11.5)

0.174

 FACIT-F

2 (–2.5, 7.5)

2.0 (–2.0, 5.0)

2 (–2.3, 5.1)

0.744

FACT-Taxane *

n = 6

n = 5

n = 11

 
 

3 (0.62, 13.5)

–5.0 (–9.0, –2.0)

0.0 (–5.0, 2.8)

0.066

FACT-BP (Bone Pain)**

n = 10

n = 14

n = 24

 
 

2 (0, 3.8)

–3.0 (–5.8, 0.8)

0 (–4.3, 3.3)

0.205

HADS

n = 27

n = 23

n = 50

 
 

-2 (-3.5, 0.5)

1.0 (–2.0, 3.5)

–1.0 (–3.0, 2.0)

0.022

  1. FACT-B Functional Assessment of Cancer Therapy—Breast, FACT-ES Functional Assessment of Cancer Therapy—Endocrine scale, FACIT Functional Assessment of Chronic Illness Therapy—Fatigue Scale, FACT-G Functional Assessment of Cancer Therapy—General, FACT-BP Functional Assessment of Cancer Therapy—Bone pain, FACT-T Functional Assessment of Cancer Therapy—Breast Taxane, HADS Hospital Anxiety and Depression Scale.
  2. *Only patients receiving taxanes.
  3. **Only patients with bone metastases.
Back to article page